These results suggest a possible therapeutic strategy with checkpoint inhibitors, since CCL5 deficiency in the mouse CRC model up-regulated the expression of programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1), and reduced the resistance to anti-PD-1 antibody [128]. The gene discussed is PDCD1; the disease is colorectal carcinoma.